Atai Beckley Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Atai Beckley N.V. (NASDAQ: ATAI) is a clinical-stage biopharmaceutical company focused on researching, developing, and commercializing evidence-based mental health treatments, particularly psychedelic-based neuroplastogens and related therapies targeting unmet needs in psychiatry such as treatment-resistant depression (TRD), alcohol use disorder, social anxiety disorder, schizophrenia-associated cognitive impairment, and major depressive disorder. The company offers a diversified pipeline including BPL-003, an intranasal mebufotenin benzoate nasal spray in Phase 2b/3-ready studies for TRD and alcohol use disorder with U.S. FDA Breakthrough Therapy designation; VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine (DMT) in Phase 2 for TRD with topline data expected in late 2026; EMP-01 (oral R-MDMA) in Phase 2a for social anxiety disorder with results anticipated in Q1 2026; RL-007, an oral pro-cognitive neuromodulator in Phase 2b for cognitive impairment associated with schizophrenia; ELE-101, a serotonergic psychedelic in Phase 2a for major depressive disorder; and preclinical non-hallucinogenic 5-HT2A receptor agonists EGX-A and EGX-B for TRD. Founded in 2018 and headquartered in Berlin, Germany, with additional operations in New York, London, the United States, and Canada, Atai Beckley advances scalable, rapid-acting in-clinic treatments designed for single-dose administration and short psychedelic duration to improve patient outcomes across large populations. In a major strategic development completed in November 2025, the company resulted from the all-share business combination between atai Life Sciences N.V. and Beckley Psytech Limited, valuing Beckley at approximately $390 million and integrating its assets including BPL-003 while issuing about 105 million new shares representing 31% ownership to Beckley shareholders; this followed atai's January 2024 $50 million investment acquiring a 36% stake in Beckley and a concurrent $30 million private placement from investors including Ferring Ventures and Adage Capital Partners. The transaction enhances Atai Beckley's leadership in psychedelic therapies, bolstering its intellectual property portfolio and pipeline scalability amid a global mental health crisis affecting over one billion people.
Company News
Why Is AtaiBeckley Inc (ATAI) Up 0.8% Since Last Earnings Report?
Lilly Builds Neuroscience into a New Long-Term Growth Driver
Jim Cramer Isn't Sure If There's Upside In This Health Care Stock
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?
Are DSGR, HLX, ATAI, CRNX Obtaining Fair Deals for their Shareholders?
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
Wall Street Analysts Predict a 31.48% Upside in AtaiBeckley Inc (ATAI): Here's What You Should Know
Are SOLS, LXP, ATAI Obtaining Fair Deals for their Shareholders?
Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.
ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly
ATAI Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Proposed Sale of AtaiBeckley to Eli Lilly
Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here's What You Need to Know.
How Much Upside is Left in AtaiBeckley Inc (ATAI)? Wall Street Analysts Think 33.33%
Are PSNL, LXP, DSGR, ATAI Obtaining Fair Deals for their Shareholders?
AtaiBeckley Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of AtaiBeckley Inc. - ATAI
Deal Dispatch: Uber Buys Delivery Hero For $14.8 Billion, Eli Lilly Acquires AtaiBeckley, Lulu's Fashion Considers Strategic Alternatives
Eli Lilly to Boost Neuroscience Pipeline With AtaiBeckley Buyout